Rappuoli R, Pizza M, Del Giudice G, De Gregorio E. Vaccines, new opportunities for a new society. Proc Natl Acad Sci. 2014;111:12288–93.
Article CAS PubMed PubMed Central Google Scholar
Pollard AJ, Bijker EM. A guide to vaccinology: from basic principles to new developments. Nat Rev Immunol. 2021;21:83–100.
Article CAS PubMed Google Scholar
Morens DM, Fauci AS. Emerging pandemic diseases: how we got to COVID-19. Cell. 2020;182:1077–92.
Article CAS PubMed PubMed Central Google Scholar
Hajj KA, Whitehead KA. Tools for translation: non-viral materials for therapeutic mRNA delivery. Nat Rev Mater. 2017;2:17056.
Nanomedicine and the COVID-19 vaccines. Nat Nanotechnol. 2020;15, 963–963.
Gebre MS, Brito LA, Tostanoski LH, Edwards DK, Carfi A, Barouch DH. Novel approaches for vaccine development. Cell. 2021;184:1589–603.
Article CAS PubMed PubMed Central Google Scholar
Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, et al. Direct gene transfer into mouse muscle in vivo. Science. 1990;247:1465–8.
Article CAS PubMed Google Scholar
Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines—a new era in vaccinology. Nat Rev Drug Discov. 2018;17:261–79.
Article CAS PubMed PubMed Central Google Scholar
Guan S, Rosenecker J. Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems. Gene Ther. 2017;24:133–43.
Article CAS PubMed Google Scholar
Zhang X, Goel V, Robbie GJ. Pharmacokinetics of patisiran, the first approved RNA interference therapy in patients with hereditary transthyretin-mediated amyloidosis. J Clin Pharmacol. 2020;60:573–85.
Article CAS PubMed Google Scholar
Urits I, Swanson D, Swett MC, Patel A, Berardino K, Amgalan A, et al. A review of patisiran (ONPATTRO®) for the treatment of polyneuropathy in people with hereditary transthyretin amyloidosis. Neurol Ther. 2020;9:301–15.
Article PubMed PubMed Central Google Scholar
Akinc A, Maier MA, Manoharan M, Fitzgerald K, Jayaraman M, Barros S, et al. The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs. Nat Nanotechnol. 2019;14:1084–7.
Article CAS PubMed Google Scholar
Kim YC, Dema B, Reyes-Sandoval A. COVID-19 vaccines: breaking record times to first-in-human trials. Npj Vaccines. 2020;5:34.
Article CAS PubMed PubMed Central Google Scholar
Friedrichs S, Bowman DM. COVID-19 may become nanomedicine’s finest hour yet. Nat Nanotechnol. 2021;16:362–4.
Article CAS PubMed Google Scholar
Schoenmaker L, Witzigmann D, Kulkarni JA, Verbeke R, Kersten G, Jiskoot W, et al. mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability. Int J Pharm. 2021;601:120586.
Article CAS PubMed PubMed Central Google Scholar
Crommelin DJA, Anchordoquy TJ, Volkin DB, Jiskoot W, Mastrobattista E. Addressing the cold reality of mRNA vaccine stability. J Pharm Sci. 2021;110:997–1001.
Article CAS PubMed Google Scholar
Gilleron J, Querbes W, Zeigerer A, Borodovsky A, Marsico G, Schubert U, et al. Image-based analysis of lipid nanoparticle–mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat Biotechnol. 2013;31:638–46.
Article CAS PubMed Google Scholar
Sabnis S, Kumarasinghe ES, Salerno T, Mihai C, Ketova T, Senn JJ, et al. A novel amino lipid series for mRNA delivery: improved endosomal escape and sustained pharmacology and safety in non-human primates. Mol Ther. 2018;26:1509–19.
Article CAS PubMed PubMed Central Google Scholar
Chapin-Bardales J, Gee J, Myers T. Reactogenicity following receipt of mRNA-based COVID-19 vaccines. JAMA. 2021;325:2201–2.
Article CAS PubMed Google Scholar
Cheng Q, Wei T, Farbiak L, Johnson LT, Dilliard SA, Siegwart DJ. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR–Cas gene editing. Nat Nanotechnol. 2020;15:313–20.
Article CAS PubMed PubMed Central Google Scholar
Dammes N, Goldsmith M, Ramishetti S, Dearling JLJ, Veiga N, Packard AB, et al. Conformation-sensitive targeting of lipid nanoparticles for RNA therapeutics. Nat Nanotechnol. 2021;16:1030–8.
Article CAS PubMed PubMed Central Google Scholar
Wilhelm S, Tavares A, Dai Q, Ohta S, Audet J, Dvorak HF, et al. Analysis of nanoparticle delivery to tumours. Nat Rev Mater. 2016;1:16014.
Jiang W, Kim BYS, Rutka JT, Chan WCW. Nanoparticle-mediated cellular response is size-dependent. Nat Nanotechnol. 2008;3:145–50.
Article CAS PubMed Google Scholar
Conner SD, Schmid SL. Regulated portals of entry into the cell. Nature. 2003;422:37–44.
Article CAS PubMed Google Scholar
Rejman J, Oberle V, Zuhorn IS, Hoekstra D. Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem J. 2004;377:159–69.
Article CAS PubMed PubMed Central Google Scholar
Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov. 2010;9:615–27.
Article CAS PubMed Google Scholar
Andar AU, Hood RR, Vreeland WN, DeVoe DL, Swaan PW. Microfluidic preparation of liposomes to determine particle size influence on cellular uptake mechanisms. Pharm Res. 2014;31:401–13.
Article CAS PubMed Google Scholar
Evers MJW, Kulkarni JA, Van der Meel R, Cullis PR, Vader P, Schiffelers RM. State-of-the-art design and rapid-mixing production techniques of lipid nanoparticles for nucleic acid delivery. Small Methods. 2018;2:1700375.
Hoshyar N, Gray S, Han H, Bao G. The effect of nanoparticle size on in vivo pharmacokinetics and cellular interaction. Nanomed. 2016;11:673–92.
Chauhan VP, Jain RK. Strategies for advancing cancer nanomedicine. Nat Mater. 2013;12:958–62.
Article CAS PubMed PubMed Central Google Scholar
Le-Vinh B, Steinbring C, Wibel R, Friedl JD, Bernkop-Schnürch A. Size shifting of solid lipid nanoparticle system triggered by alkaline phosphatase for site specific mucosal drug delivery. Eur J Pharm Biopharm. 2021;163:109–19.
Article CAS PubMed Google Scholar
Trevaskis NL, Kaminskas LM, Porter CJH. From sewer to saviour—targeting the lymphatic system to promote drug exposure and activity. Nat Rev Drug Discov. 2015;14:781–803.
Article CAS PubMed Google Scholar
Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20:101–24.
Article CAS PubMed Google Scholar
Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33:941–51.
Article CAS PubMed PubMed Central Google Scholar
Demelenne A, Servais AC, Crommen J, Fillet M. Analytical techniques currently used in the pharmaceutical industry for the quality control of RNA-based therapeutics and ongoing developments. J Chromatogr. A. 2021;1651:462283.
Article CAS PubMed Google Scholar
Fan Y, Marioli M, Zhang K. Analytical characterization of liposomes and other lipid nanoparticles for drug delivery. J Pharm Biomed Anal. 2021;192:113642.
Article CAS PubMed Google Scholar
Malburet C, Leclercq L, Cotte JF, Thiebaud J, Bazin E, Garinot M, et al. Size and charge characterization of lipid nanoparticles for mRNA vaccines. Anal Chem. 2022;94:4677–85.
Article CAS PubMed Google Scholar
Chamieh J, Leclercq L, Martin M, Slaoui S, Jensen H, Østergaard J, et al. Limits in size of taylor dispersion analysis: repre
留言 (0)